Global Renal Denervation Market – Industry Trends and Forecast to 2030

Global Renal Denervation Market, By Product (Simplicity Renal Denervation System, Enlightn, Vessix Renal Denervation System, Paradise Renal Denervation System, Iberis Renal Sympathetic Denervation System), Technology (Radiofrequency, Ultrasound, Micro-Infusion, Pharmacologic), Type (Catheters, RF Generator, Nerve Modifying Agents), Indication (Hypertension, Heart Failure, Diabetes, Renal Failure), End User (Hospitals, Specialty Clinics, Research and Academic Institutes, Ambulatory Care Centers) – Industry Trends and Forecast to 2030.

Renal Denervation Market Analysis and Size

The rising prevalence of hypertension as well as the increasing preference for minimally invasive procedures for treatment have carved the way for the growth of renal denervation products. These provide precisely controlled and targeted Radiofrequency (RF) energy to the renal nerves which disrupt the overactive sympathetic signaling between the kidneys and brain to reduce blood pressure.

The increase in the prevalence of resistant hypertension is leading to an increase in the number of patients seeking treatment along with the rising preference of healthcare providers towards minimally invasive procedures for the treatment of resistant hypertension using renal denervation technique. For instance, according to WHO, around 1.28 billion people aged between 30 and 79 years were affected by hypertension globally in 2021.

An increase in the number of cases of hypertension is expected to create demand for renal denervation devices during the forecast period. Some major reasons for an increase in the prevalence of hypertension are the increasing geriatric population, high sodium and low potassium intake, rising cases of obesity, increasing alcohol consumption in low and middle-income countries, physical inactivity, and the lack of a balanced diet.                         

Data Bridge Market Research analyzes that the global renal denervation market which was USD USD 789.43 million in 2022, would rocket up to USD 7,101.66 million by 2030, and is expected to undergo a CAGR of 31.60% during the forecast period. This indicates the market value. The “Hospitals” segment dominates the end user segment of the global renal denervation market owing to the growing demand for renal denervation. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Renal Denervation Market Scope and Segmentation

Market Definition

Renal denervation is a minimally-invasive catheter-based treatment that is used for hypertension. Radiofrequency ablation is used to burn nerves in the renal arteries. Nerve activity decreases and blood pressure decreases. If pharmacological treatment does not result in relief, this procedure is usually used to achieve better results. The nerves in the renal artery wall are removed using high-frequency pulses or ultrasound. It lowers blood pressure by reducing the activity of the sympathetic kidneys.

An increase in hypertension, heart failure, and chronic kidney disease indicates a significant and growing global health issue. Recently therapeutic strategies for these conditions are mainly based on lifestyle interventions and pharmacological approaches, but the rates of control of blood pressure and the therapeutic efforts to prevent the progression of heart failure need additional options. Renal denervation is a novel nonpharmacological intervention that involves a catheter-based ablation of the sympathetic nerve. Various technologies are used to detect in which the choice of each technique should be based upon the availability of resources according to patient requirements.

Global Renal Denervation Market Dynamics

Drivers

• Increasing  prevalence of hypertension

Hypertension is becoming very common due to many factors such as depression, stress, co-morbid conditions, and several other factors. Renal denervation therapy has shown positive results to treat hypertension via using various forms of energy such as radiofrequency and ultrasound. It is proven to be effective in decreasing blood pressure both in the short and long term. Moreover, it reduces activity in renal nerves in kidneys to help lower blood pressure. For instance, according to the American Heart Association, more than 29 million people are estimated to have Blood Pressure (BP) exceeding professional society and guideline-recommended treatment goals in the U.S. alone in 2021.

• Associated  beneficial factors

Renal denervation therapy has shown positive results in reducing hypertension. Therefore, the benefits offered by these therapies, such as long-lasting effects, shorter treatment times, and higher safety, are expected to drive market growth. In addition, advances in renal denervation devices have the potential to drive market growth. For instance, the development of catheter-based interventions to remove renal nerves has shown impressive results in managing blood pressure in patients with resistant hypertensive symptoms. In addition, catheter-based procedures appear to be safer for the patient and facilitate the denervation of selected nerves.

• Increase in clinical trials 

An increase in clinical studies and R&D associated with renal denervation devices and the long-term benefits of renal denervation procedures are expected to drive market growth. For instance, in April 2022, as per the article published in Nature, more than 80% of Thai patients with resistant hypertension experienced the success of the renal nerve denervation outcome, which was sustained over a longer follow-up without any intervention-related side effects.

Opportunities

• Increase in healthcare expenditure and funding for research and clinical activities

The expansion of money used by a country on its healthcare and its growth rate over time is inclined by a wide variety of economic and social factors, including the financial agreements and structure of the organization of the health system. This will further create lucrative market growth opportunities. Furthermore, an upsurge in the public-private funding for target research activities, increasing chronic diseases, and rising product innovations and development demand owing to technological advancements all around the world are expected to provide profitable opportunities for market players in the forecast period of 2023 to 2030.

• Rising number of chronic diseases

Increasing the patient pool of other chronic diseases such as obesity among children and adults is expected to create opportunities for market growth in the forecast period.

As per the WHO’s statistics, over 39 million children aged below 5 years were overweight in 2021. This condition is likely to push the demand for renal nerve denervation therapy, as high leptin levels in obese people can trigger the growth of blood vessels in the hypothalamus, thereby causing hypertension.

• Development of new techniques

The number of new skills introduced in the renal denervation approach is one of the main factors accelerating its adoption. A renal denervation system incorporating ultrasonic technology can overcome the limitations of high-frequency-based renal denervation systems. High-frequency sound waves with ultrasonic energy help remove nerves without close contact with tissue. This helps prevent damage to the renal arteries. Due to this characteristic, a significant number of patients around the world prefer this technique. In addition, integrating technology into these types of healthy habits will significantly improve the outcome of these techniques.

Restraints/Challenges

• Risk of post-surgery infection

One of the main factors limiting the demand for renal denervation is the risk of infection that can be caused after surgery. All types of surgery involving skin cuts, incisions, or other interventions can cause infections in the patient's body. In most cases, infections in surgical wounds are seen one month after surgery. Postoperative infections can cause a variety of problems with wounds and the patient's body. For instance, surgical wound infections can ejaculate pus through the incision. In addition, these infections are very painful and cause swelling and inflammation of the wound.

• High cost of renal denervation

Renal denervation is a procedure aimed at reducing blood pressure in resistant hypertension patients by decreasing efferent sympathetic signaling to the kidneys, however, the procedure is costly. The high cost of these techniques is expected to restrain market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global renal denervation market, contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In April 2021, Brattea, a leading company in renal denervation in China, completed over USD 20 million by Kuanping Capital. This led to the expansion of the product portfolio into several other promising indications
• In April 2021, Medtronic partnered with Surgical Theater, a developer of technology based on flight simulation of fighter aircraft for patients. Following this partnership, Medtronic would integrate the Stealth Station S8 Surgical Navigation System with Surgical Theater's SyncAR Augmented Reality technology to enable neurosurgeons to use real-time AR technology to improve visualization during difficult cranial surgery
• In December 2020, FDA granted breakthrough therapy device designation to two renal denervation systems ReCor Medical, Inc, and SoniVie

Global Renal Denervation Market Scope

The global renal denervation market is segmented into five notable segments based on product, technology, type, indication, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Simplicity Renal Denervation System
• Enlightn
• Vessix Renal Denervation System
• Paradise Renal Denervation System
• Iberis Renal Sympathetic Denervation System

Technology

• Radiofrequency
• Ultrasound
• Micro-Infusion
• Pharmacologic

Type

• Catheters
• RF Generator
• Nerve Modifying Agents

Indication

• Hypertension
• Heart Failure
• Diabetes
• Renal Failure

End-User

• Hospitals
• Specialty Clinics
• Research and Academic Institutes
• Ambulatory Care Centers

Global Renal Denervation Market Regional Analysis/Insights

The global renal denervation market is analyzed and market size insights and trends are provided by country, product, technology, type, indication, and end user as referenced above.

The countries covered in the global renal denervation market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.   

North America dominates the global renal denervation market due to the growing number of R&D activities along with changing lifestyle of the population.

Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 due to the increasing prevalence of obesity and diabetes along with the increasing number of drug-resistant hypertension cases.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global renal denervation market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global renal denervation market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the market. The data is available for the historic period 2010-2021.

Competitive Landscape and Global Renal Denervation Market Share Analysis

The global renal denervation market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major market players operating in the global renal denervation market are:

• Medtronic (U.S.)
• Boston Scientific Corporation (U.S.)
• Abbott (U.S.)
• ReCor Medical, Inc. (U.S.)
•  Johnson & Johnson Private Limited (U.S.)
• Terumo Corporation (Japan)
• Mercator MedSystems,Inc. (U.S.)
• Ablative Solutions, Inc. (U.S.)
• SympleSurgical Inc. (U.S.)
• Kona Medical Inc. (U.S.)
• Renal Dynamics Limited (U.K.)
• Otsuka Medical Devices Co., Ltd. (Tokyo)